Immunogenicity subcohort, case-cohort sets, and COVID-19 endpoints
The demographic and clinical characteristics of participants in the randomly sampled immunogenicity subcohort (1010 vaccine recipients and 137 placebo recipients), as well as participant flow from enrollment through inclusion in the D29 or D57 marker case-cohort set, have been described (